Facebook
Twitter
LinkedIn
ForwardMaintenance of Certification Exam Preparation Course
This on-demand course helps you thoroughly prepare for the American Board of Psychiatry and Neurology (ABPN) Maintenance of Certification exam and grants 45.75 AMA PRA Category 1 Credits™.
It contains more than 45 chapterized sessions that review all the important topics covered in the ABPN exam.
- Psychiatric disorders: anxiety, mood disorders, substance-related disorders, schizophrenia, eating disorders, and more
- Basic concepts: behavioral and social sciences, development through the lifecycle, diagnostic procedures, epidemiology and public policy
- Plus, sessions on suicide, psychotherapy, general principles of psychopharmacology, neurology, violence and risk assessment, emergency psychiatry, and more.
Every session is led by experts from the Massachusetts General Hospital Department of Psychiatry, which has been named #1 in the country 17 times by U.S. News & World Report.
The faculty list includes renowned clinician-researchers such as Eugene V. Beresin, MD, Oliver Freudenreich, MD, FAPM, John F. Kelly, PhD, Andrew A. Nierenberg, MD, and many more.
The chapterized content lets you easily search for and review important information as often as you want, and all sessions were developed with consideration for the DSM-5 diagnostic criteria. Plus, the course content is fully accessible via smartphones and tablets so you can participate from your home, office or anywhere else.
Pricing
This course is available now for $895.00. You will have access to the content through _____.
Cancellation Policy
Course: Cancellation requests must be made within 10 business days after the initial purchase to receive a refund minus a $100.00 administrative fee. No refunds will be made thereafter.
Book Purchase: Refund requests for books purchased with the course package will be honored if made within 10 business days of merchandise delivery, for books returned that are in excellent condition. No refunds will be made for requests that come in more than 10 days after receipt, or for books returned that are not in excellent condition.
By clicking "Register" you acknowledge that you fully understand these policies.
Target Audience
This course is intended for psychiatrists studying for the Maintenance of Certification (MOC) examination.
Learning Objectives
- Review the primary epidemiologic and evidence-based diagnostic, assessment, and treatment modalities for psychiatry.
- Recognize recent sentinel research findings that inform clinical best practices.
- Identify commonly encountered ethical issues and resolution strategies.
- Demonstrate ability to recall and apply relevant scientific and clinical information in the ares of psychiatry and neurology that the ABPN identifies as topics for the maintenance of certification exam.
Topics covered by expert faculty include:
| Topic Title | Faculty Presenter |
| Alcohol Use Disorder | John A. Renner, MD |
| Antipsychotics | Oliver Freudenreich, MD, FAPM |
| Anxiety Disorders | Mireya F. Nadal-Vicens, MD, PhD |
| Bipolar Disorder | Andrew A. Nierenberg, MD |
| Cerebrovascular Disorders | Erica Camargo Faye, MD, MMSc |
| Child Psychiatry I | David H. Rubin, MD |
| Child Psychiatry II | Robert R. Althoff, MD, PhD |
| Cognitive Behavioral Therapy (CBT) | Susan Sprich, PhD |
| Culture, Ethnicity and Psychiatry | Nhi-Ha Trinh, MD |
| Delirium | Theodore A. Stern, MD |
| Drug Interactions | Jonathan E. Alpert, MD, PhD |
| Eating Disorders | Jennifer J. Thomas, PhD |
| Emergency Psychiatry | Curtis W. Wittmann, MD |
| Epilepsy | Zeina N. Chemali, MD, MPH |
| Family Therapy | Anne K. Fishel, PhD |
| Genetics & Psychiatry | Mireya F. Nadal-Vicens, MD, PhD |
| Geriatric Psychiatry | James Ellison, MD, MPH |
| Headache | Shamim H. Nejad, MD |
| Learning Disorders | Ellen Braaten, PhD |
| Mood and Adjustment Disorders | David Mischoulon, MD, PhD |
| Movement Disorders | Albert Y. Hung, MD, PhD |
| Neural Development Through the Life Cycle | Robert R. Althoff, MD, PhD |
| Neurocognitive Disorders | James Ellison, MD, PhD |
| Neuroimaging | Darin D. Dougherty, MD, MMSc |
| Neurotherapeutics | Darin D. Dougherty, MD, MMSc |
| Neurotransmitters & Receptors | Dost Ongur, MD, PhD |
| Obsessive-Compulsive Disorder (OCD) | Darin D. Dougherty, MD, MMSc |
| Opioids | John A. Renner, MD |
| Pain Syndromes and Management | Peter M. Thomashow, MD |
| Perinatal Mood Disorders | Marlene P. Freeman, MD |
| Personality Disorders | Asha I. Parekh, MD |
| Pharmacokinetics and Pharmacodynamics | Robert R. Althoff, MD, PhD |
| Psychiatric Ethics, Risk Assessment & Forensics | Ronald Schouten, MD, JD |
| The Principles of Psychosomatic Medicine and Consultation Psychiatry | Gregory L. Fricchione, MD |
| Psychiatric Interview | Eugene Beresin, MD, MA |
| Psychoanalytic Theory | Margaret Cramer, PhD |
| Psychodynamic Theory & Therapy | Raymond A. Levy, PsyD |
| Psychological Assessment | Mark Blais, PsyD |
| Psychosocial Interventions | Corinne Cather, PhD |
| PTSD and Complicated Grief | T.H. Eric Bui, MD, PhD |
| Public Policy and Healthcare Economics | Bradley V. Watts, MD |
| Rating Scales and Clinical Assessment Tools | John F. Kelly, PhD |
| Research Design and Biostatistics | Robert R. Althoff, MD, PhD |
| Schizophrenia | Oliver Freudenreich, MD, FAPM |
| Sleep Disorders | Theodore A. Stern, MD |
| Somatic Symptom & Related Disorders and Dissociative Disorders | Guy Maytal, MD |
| Suicide | Theodore A. Stern, MD |
| Transgender Youth | Amy C. Tishelman, PhD |
| Treating Mood Disorders | Maurizio Fava, MD |
| Violence and Risk Assessment | Renee Sorrentino, MD |
Jonathan E. Alpert, MD, PhD
Robert R. Althoff, MD, PhD
Eugene V. Beresin, MD
Mark Blais, PsyD
Ellen B. Braaten, PhD
T. H. Eric Bui, MD, PhD
Zeina N. Chemali, MD, MPH
David W. Chen, MD
Darin D. Dougherty, MD, MMSc
James M. Ellison, MD, MPH
Anne K. Fishel, PhD
Marlene P. Freeman, MD
Oliver Freudenreich, MD, FAPM
Albert Hung, MD, PhD
John F. Kelly, PhD
Raymond Levy, PsyD
Guy Maytal, MD
James W. McKowen, PhD
David Mischoulon, MD, PhD
Mireya Nadal-Vicens, MD, PhD
Andrew A. Nierenberg, MD
Dost Ongür, MD, PhD
George I. Papakostas, MD
John A. Renner, MD
David H. Rubin, MD
Ronald Schouten, MD, JD
Renee Sorrentino, MD
Susan E. Sprich, PhD
Theodore A. Stern, MD
Jennifer J. Thomas, PhD
Amy C. Tishelman, PhD
Bradley V. Watts, MD
Curtis Wittmann, MD
Nhi-Ha Trinh, MD, MPH
Available Credit
- 45.75 AMA PRA Category 1 Credit™
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of McLean Hospital and Massachusetts General Hospital. McLean Hospital is accredited by the ACCME to provide continuing medical education for physicians.
McLean Hospital designates this Enduring activity for a maximum of 45.75 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
- 45.75 Participation
This course allows other providers to claim a Participation Certificate upon successful completion of this course.
Participation Certificates will specify the title, location, type of activity, date of activity, and number of AMA PRA Category 1 Credit™ associated with the activity. Providers should check with their regulatory agencies to determine ways in which AMA PRA Category 1 Credit™ may or may not fulfill continuing education requirements. Providers should also consider saving copies of brochures, agenda, and other supporting documents.
Price
On Demand Event Details
Release Date: December 4, 2015
Expiration Date: July 18, 2027
Review Date: December 27, 2020 by Robert Althoff, MD
Accreditation Statement
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of McLean Hospital and Massachusetts General Hospital. McLean Hospital is accredited by the ACCME to provide continuing medical education for physicians.
McLean Hospital designates this enduring material for a maximum of 45.75 AMA PRA Category 1 CreditsTM
2017 Planners
David H. Rubin, MD, reviewer
Jane Pimental, MPH
Susan E. Sprich, PhD, psychologist reviewer
Michael Hirsch, MD
Robert Althoff, MD, reviewer
2015 Planners
David H. Rubin, MD, reviewer
Jane Pimental, MPH
Susan E. Sprich, PhD, psychologist reviewer
Michael Hirsch, MD
Robert Althoff, MD, reviewer
Disclosure Information
In accord with the disclosure policy of Massachusetts General Hospital Psychiatry Academy as well as guidelines set forth by the Accreditation Council on Continuing Medical Education, all people in control of educational content, including speakers, course directors, planners, and reviewers, have been asked to disclose all relevant financial relationships with commercial interests of both themselves and their spouses/partners over the past 12 months, as defined below:
Commercial Interest
The ACCME defines a “commercial interest” as any entity producing, marketing, re-selling, or distributing health care goods or services, used on, or consumed by, patients. The ACCME does not consider providers of clinical service directly to patients to be commercial interests. For more information, visit www.accme.org.
Financial relationships
Financial relationships are those relationships in which the individual benefits by receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received, or expected. ACCME considers relationships of the person involved in the CME activity to include financial relationships of a spouse or partner.
Relevant financial relationships
ACCME focuses on financial relationships with commercial interests in the 12-month period preceding the time that the individual is being asked to assume a role controlling content of the CME activity. ACCME has not set a minimal dollar amount for relationships to be significant. Inherent in any amount is the incentive to maintain or increase the value of the relationship. The ACCME defines “’relevant’ financial relationships” as financial relationships in any amount occurring within the past 12 months that create a conflict of interest.
Conflict of Interest
Circumstances create a conflict of interest when an individual has an opportunity to affect CME content about products or services of a commercial interest with which he/she has a financial relationship.
The following planners, speakers, and content reviewers, on behalf of themselves and their spouse or partner, have reported financial relationships with an entity producing, marketing, re-selling, or distributing health care goods or services (relevant to the content of this activity) consumed by, or used on, patients:
2017 Planner Disclosure Information
Robert Althoff, MD, planner
Speaker and Organizer Fee: Oakstone Publishing
Grant Support: National Institute of General Medical Sciences, Klingenstein Third Generation Foundation
Partial Salary and Research Support, Ownership Interest: Research Center for Children, Youth, and Families, WISER Systems, LLC
Susan E. Sprich, PhD, psychologist reviewer, planner
Royalties (Co-Authoring Books): Oxford University Press
Royalties (Co-Editing Book): Springer
2015 Disclosure Information
Mike Hirsch, MD, planner
Royalties: UpToDate Inc. (medical writing)
Susan E. Sprich, PhD, psychologist reviewer, planner
Royalties: Oxford University Press (for co-authoring treatment manual and client workbook), Springer (for editing book)
Robert Althoff, MD, planner
Grant Funding (Research): National Institute of Mental Health and National Institute of General Medical Sciences,
Grant Funding (Mentorship Program): Klingenstein Third Generation Foundation
Salary Support (Research): Nonprofit Research Center for Children Youth Families
Speaker fee: Oakstone publishing
Ownership interest: Families WISER Systems, LLC
Jonathan Alpert, MD, PhD
Speaker Honoraria: American Society of Clinical Psychopharmacology, American Psychiatric Association, Janssen Nevada Psychiatric Association North Shore Medical Center Psicofarma Reed Medical Education University of Louisville
Royalties: Belvoir Publishing, Marcel Dekker Institut la Conference Hippocrate
Consultant Fees: PamLab LLC, Luye Pharmaceuticals
Research Support: Abbott Labs, Alkermes, Aspect Medical Systems, Astra-Zeneca, Bristol-Myers Squibb, Cephalon, Eli Lilly Co., Forest Pharmaceuticals, GlaxoSmithKline, J J Pharmaceuticals, Lichtwer Pharma, Novartis, Organon, PamLab LLC, Pharmavite, Roche Laboratories, Solvay Pharmaca, Sanofi/Synthelabo, Wyeth-Ayerst
Robert Althoff, MD
Grant Funding (Research): National Institute of Mental Health and National Institute of General Medical Sciences,
Grant Funding (Mentorship Program): Klingenstein Third Generation Foundation
Salary Support (Research): Nonprofit Research Center for Children Youth Families
Darin D. Dougherty, MD, MMSc
Research Support: Medtronic Cyberonics, Eli Lilly, Roche
Consultation Fee: Insys
Speaker Fee: Johnson Johnson
Maurizio Fava, MD
Consultant (Paid Research Support/Lifetime: Abbot Laboratories, Alkermes Inc., American Cyanamid, Aspect Medical Systems, AstraZeneca, Avanir Pharmaceuticals, BioResearch, BrainCells Inc., Bristol-Myers Squibb, CeNeRx BioPharma, Cephalon, Clintara LLC, Covance, Covidien, Eli Lilly and Company, EnVivo Pharmaceuticals Inc., Euthymics Bioscience Inc., Forest Pharmaceuticals Inc., Ganeden Biotech Inc., GlaxoSmithKline, Harvard Clinical Research Institute, Hoffman-LaRoche, Icon Clinical Research, i3 Innovus/Ingenix, Janssen R D LLC, Jed Foundation, Johnson Johnson Pharmaceutical Research Development, Lichtwer Pharma GmbH, Lorex Pharmaceuticals, Lundbeck Inc., MedAvante, Methylation Sciences Inc, National Alliance for Research on Schizophrenia Depression NARSAD, National Center for Complementary and Alternative Medicine NCCAM, National Institute of Drug Abuse NIDA, National Institute of Mental Health NIMH, Neuralstem Inc., Novartis AG, Organon Pharmaceuticals, PamLab LLC., Pfizer Inc., Pharmacia-Upjohn, Pharmaceutical Research Associates. Inc., Pharmavite LLC, PharmoRx Therapeutics, Photothera, Reckitt Benckiser, Roche Pharmaceuticals, RCT Logic LLC formerly Clinical Trials Solutions LLC, Sanofi-Aventis US LLC, Shire, Solvay Pharmaceuticals Inc., Stanley Medical Research Institute SMRI, Synthelabo, Wyeth-Ayerst Laboratories
Consultant (Paid Directly to MGH): Advisory Board/ Consultant/Lifetime: Abbott Laboratories, Affectis Pharmaceuticals AG, Alkermes Inc., Amarin Pharma Inc., Aspect Medical Systems, AstraZeneca, Auspex Pharmaceuticals, Avanir Pharmaceuticals, AXSOME Therapeutics, Bayer AG, Best Practice Project Management Inc., BioMarin Pharmaceuticals Inc., Biovail Corporation, BrainCells Inc, Bristol-Myers Squibb, CeNeRx BioPharma, Cephalon Inc., Cerecor, CNS Response Inc., Compellis Pharmaceuticals, Cypress Pharmaceutical Inc., DiagnoSearch Life Sciences P Ltd., Dinippon Sumitomo Pharma Co. Inc., Dov Pharmaceuticals Inc., Edgemont Pharmaceuticals Inc., Eisai Inc., Eli Lilly and Company, EnVivo Pharmaceuticals Inc., ePharmaSolutions, EPIX Pharmaceuticals Inc., Euthymics Bioscience Inc., Fabre-Kramer Pharmaceuticals Inc., Forest Pharmaceuticals Inc., Forum Pharmaceuticals, GenOmind LLC, GlaxoSmithKline, Grunenthal GmbH, i3 Innovus/Ingenis, Janssen Pharmaceutica, Jazz Pharmaceuticals Inc., Johnson Johnson Pharmaceutical Research Development LLC, Knoll Pharmaceuticals Corp., Labopharm Inc., Lorex Pharmaceuticals, Lundbeck Inc., MedAvante Inc., Merck Co. Inc., MSI Methylation Sciences Inc., Naurex Inc., Nestle Health Sciences, Neuralstem Inc., Neuronetics Inc., NextWave Pharmaceuticals, Novartis AG, Nutrition 21, Orexigen Therapeutics Inc., Organon Pharmaceuticals, Otsuka Pharmaceuticals, Pamlab LLC., Pfizer Inc., PharmaStar, Pharmavite LLC., PharmoRx Therapeutics, Precision Human Biolaboratory, Prexa Pharmaceuticals Inc., PPD, Puretech Ventures, PsychoGenics, Psylin Neurosciences Inc., RCT Logic LLC formerly Clinical Trials Solutions LLC, Rexahn Pharmaceuticals Inc., Ridge Diagnostics Inc., Roche, Sanofi-Aventis US LLC., Sepracor Inc., Servier Laboratories, Schering-Plough Corporation, Solvay Pharmaceuticals Inc., Somaxon Pharmaceuticals Inc., Somerset Pharmaceuticals Inc., Sunovion Pharmaceuticals, Supernus Pharmaceuticals Inc., Synthelabo, Takeda Pharmaceutical Company Limited, Tal Medical Inc., Tetragenex Pharmaceuticals Inc., TransForm Pharmaceuticals Inc., Transcept Pharmaceuticals Inc., Vanda Pharmaceuticals Inc.
Speaking/Publishing/Lifetime (Only from MGH Psychiatry Academy and from Belvoir Publishing for monthly newsletter editing): Adamed Co, Advanced Meeting Partners American Psychiatric Association, American Society of Clinical Psychopharmacology, AstraZeneca, Belvoir Media Group, Boehringer Ingelheim GmbH, Bristol-Myers Squibb, Cephalon Inc., CME Institute/Physicians Postgraduate Press Inc., Eli Lilly and Company, Forest Pharmaceuticals Inc., GlaxoSmithKline, Imedex LLC, MGH Psychiatry Academy/Primedia, MGH Psychiatry Academy/Reed Elsevier, Novartis AG, Organon Pharmaceuticals, Pfizer Inc., PharmaStar, United BioSource Corp., Wyeth-Ayerst Laboratories.
Stock/Other Financial Options/Lifetime: Equity Holdings (Nothing Received): Compellis, PsyBrain Inc.
Royalty/patent other income: Patents for Sequential Parallel Comparison Design SPCD licensed by MGH to Pharmaceutical Product Development LLC PPD ; and patent application for a combination of Ketamine plus Scopolamine in Major Depressive Disorder MDD licensed by MGH to Biohaven. Copyright for the MGH Cognitive Physical Functioning Questionnaire CPFQ, Sexual Functioning Inventory SFI, Antidepressant Treatment Response Questionnaire ATRQ, Discontinuation-Emergent Signs Symptoms DESS, Symptoms of Depression Questionnaire SDQ, and SAFER; Lippincott Williams Wilkins; Wolkers Kluwer; World Scientific Publishing Co. Pte.Ltd.
Marlene P. Freeman, MD
Research Grant: Takeda
Advisory Board (consultant fee): Takeda, Sunovion, JDS therapeutics
Medical Editing: GOED newsletter
Oliver Freudenreich, MD, FAPM
Research Grant: Forum, Psychogenics
Speaker Fees: Global Medical Education, MedIQ, Oakstone Medical Education
Honorarium: Beacon Health Strategies, UpToDate
Royalties: UpToDate
David Mischoulon, MD
Research Support: Bowman Family Foundation, FisherWallace, Nordic Naturals, Methylation Sciences Inc., MSI, and PharmoRx Therapeutics
Speaker Honoraria: MGH Psychiatry Academy
Royalties: Lippincott Williams Wilkins for published book Natural Medications for Psychiatric Disorders: Considering the Alternatives.
Mireya Nadal-Vicens, MD, PhD
Honoraria/travel expenses: Continuing Education Company
Andrew A. Nierenberg, MD
Consultant: Abbott Laboratories, American Psychiatric Association, Appliance Computing Inc., Mindsite, Basliea, Brain Cells Inc., Brandeis University, Bristol Myers Squibb, Clintara, Corcept Dey Pharmaceuticals, Dainippon Sumitomo now Sunovion, Eli Lilly, and Company, EpiQ, L.P./Mylan Inc., Forest Genaissance, Genentech, GlaxoSmithKline, Healthcare Global Village, Hoffman LaRoche, Infomedic, Lundbeck, Janssen Pharmaceutica, Jazz Pharmaceuticals, Medavante, Merck, Methylation Sciences, Naurex, Novartis, PamLabs, Parexel, Pfizer, PGx Health, Otsuka Ridge Diagnostics, Shire Schering-Plough, Somerset, Sunovion, Takeda Pharmaceuticals, Targacept and Teva, consulted through the MGH Clinical Trials Network and Institute CTNI for Astra Zeneca, Brain Cells Inc, Dianippon, Sumitomo/Sepracor, Johnson and Johnson, Labopharm, Merck, Methylation Science, Novartis, PGx Health, Shire Schering-Plough, Targacept, and Takeda/Lundbeck Pharmaceuticals
Grant Support: American Foundation for Suicide Prevention, AHRQ, Brain and Behavior Research Foundation, Bristol-Myers Squibb, Cederroth, Cephalon, Cyberonics, Elan, Eli Lilly, Forest, GlaxoSmithKline, Janssen Pharmaceutica, Lichtwer Pharma, Marriott Foundation, Mylan, NIMH, PamLabs, PCORI, Pfizer Pharmaceuticals, Shire, Stanley Foundation, Takeda, and Wyeth-Ayerst
Honoraria: Belvoir Publishing, University of Texas, Southwestern Dallas, Brandeis University, Bristol-Myers Squibb, Hillside Hospital, American Drug Utilization Review, American Society for Clinical Psychopharmacology, Baystate Medical Center, Columbia University, CRICO, Dartmouth Medical School, Health New England, Harold Grinspoon Charitable Foundation, IMEDEX International Society for Bipolar Disorder, Israel Society for Biological Psychiatry, Johns Hopkins University, MJ Consulting, New York State, Medscape, MBL Publishing, MGH Psychiatry Academy, National Association of Continuing Education, Physicians Postgraduate Press, SUNY Buffalo, University of Wisconsin, University of Pisa, University of Michigan, University of Miami, University of Wisconsin at Madison, APSARD, ISBD, SciMed, Slack Publishing, and Wolters Klower Publishing, ASCP, NCDEU, Rush Medical College, Yale University School of Medicine, NNDC, Nova, Southeastern University, NAMI Institute of Medicine, CME Institute, ISCTM, World Congress on Brain Behavior and Emotion, Congress of the Hellenic Society for Basic and Clinical Pharmacology, ADAA
Stock: Appliance Computing Inc., MindSite, Brain Cells Inc., Medavante
Copyright: Clinical Positive Affect Scale and the MGH Structured Clinical Interview for the Montgomery Asberg Depression Scale exclusively licensed to the MGH Clinical Trials Network and Institute CTNI
John Renner, MD
Stock Dividends: Johnson and Johnson, General Electric
Theodore A. Stern, MD
Editor-In-Chief (Psychosomatics): Academy of Psychosomatic Medicine
Royalties: MGH Psychiatry Academy
Speaker Fee: MGH Psychiatry Academy
Grant/Royalties: Elsevier
Amy Tishelman, PhD
Consulting: Abbvie Pharmaceutical research and development
All other individuals including course directors, planners, reviewers, faculty, staff, etc., who are in a position to control the content of this educational activity have, on behalf of themselves and their spouse or partner, reported no financial relationships related to the content of this activity.
Policy on Faculty and Provider Disclosure
It is the policy of Massachusetts General Hospital Psychiatry Academy that faculty and providers disclose real or apparent conflicts of interest relating to the topics of this educational activity. Massachusetts General Hospital Psychiatry Academy has established policies in place that identify and resolve all conflicts of interest prior to this educational activity.
Hardware/Software Specifications:
This internet-based CME activity is best experienced using Internet Explorer 8+, Mozilla Firefox 3+, Safari 4+. This Web site requires that JavaScript and session cookies be enabled. Certain activities may require additional software to view multimedia, presentation, or printable versions of the content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Adobe Acrobat, Microsoft PowerPoint, and Windows Media Player.
Optimal System Configuration:
Flash Player: Adobe Flash Player 10.1+
Browser: Firefox 3+, Internet Explorer 8.0+, Safari 4.0+, or Google Chrome 7.0+
Operating System: Windows XP+ or Mac OS X 10.4+
Internet Connection: 1 Mbps or higher
Minimum Requirements:
Windows PC:
500-MHz Pentium II; Windows XP or higher; 128 MB RAM; Video Card at least 64MB of video memory; Sound Card at least 16-bit; Macromedia Flash Player 10 or higher, audio playback with speakers for programs with video content; Firefox 1.1+, Internet Explorer 7.0+, Safari 1.0+, Google Chrome, or Opera
Macintosh:
Mac OS X 10.3 or higher with latest updates installed; 1.83MHz Intel Core Duo or faster; RAM: 128MB or more; Video Card: at least 64MB of video memory; Sound Card: at least 16-bitv